Performance assessment and validation of a plaque reduction neutralization test (PRNT) in support to yellow fever diagnostic and vaccine clinical trials
Journal of Medical Virology · 2023
DOI: 10.1002/jmv.28700 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Moussa Dia und 12 weiteren Autor:innen. Beteiligte Einrichtung: Virology Department, Institut Pasteur de Dakar, Dakar, Senegal. Hauptthemen laut MEDLINE: Yellow Fever, Yellow Fever Vaccine, Vaccines. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Yellow fever (YF) virus is a mosquito‐borne virus belonging to the Flaviviridae family that circulates in tropical and subtropical areas of Africa and South America. Despite the availability of an effective vaccine, YF remains a threat to travelers, residents of endemic areas, and unvaccinated populations. YF vaccination and natural infection both induce the production of neutralizing antibodies. Serological diagnostic methods detecting YF virus‐specific antibodies demonstrate high levels of cross‐reactivities with other flaviviruses. To date, the plaque reduction neutralization test (PRNT) is the most specific serological test for the differentiation of flavivirus infections and is considered the reference method for detecting YF neutralizing antibodies and assessing the protective immune response following vaccination. In this study, we developed and validated a YF PRNT. We optimized different parameters including cell concentration and virus‐serum neutralization time period and then assessed the intra‐ and inter‐assay precisions, dilutability, specificity, and lower limit of quantification (LLOQ) using international standard YF serum, sera from vaccinees and human specimens collected through YF surveillance. The YF PRNT has shown good robustness and 100% of intra‐assay precision, 95.6% of inter‐assay precision, 100% of specificity, 100% of LLOQ, and 95.3% of dilutability. The test is, therefore, suitable for use in the YF diagnostic as well as evaluation of the YF vaccine neutralizing antibody response and risk assessment studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Virology Department, Institut Pasteur de Dakar, Dakar, Senegal.
- Epidemiology, Clinical Research and Data Science Department, Institute Pasteur de Dakar, Dakar, Senegal.
- Unité Physiologie et Pathologie Moléculaires des Rétrovirus Endogènes et Infectieux, CNRS UMR 9196, Villejuif, France.
- Foundation for Innovative New Diagnostics, Geneva, Switzerland.
Zitieren
APA
Dia, M., Bob, N. S., Talla, C., Dupressoir, A., Escadafal, C., Thiam, M. S., Diallo, A., Ndiaye, O., Heraud, J. M., Faye, O., Sall, A. A., Faye, O., & Fall, G. (2023). Performance assessment and validation of a plaque reduction neutralization test (PRNT) in support to yellow fever diagnostic and vaccine clinical trials. Journal of Medical Virology. https://doi.org/10.1002/jmv.28700
Vancouver
Dia M, Bob NS, Talla C, Dupressoir A, Escadafal C, Thiam MS, et al. Performance assessment and validation of a plaque reduction neutralization test (PRNT) in support to yellow fever diagnostic and vaccine clinical trials. Journal of Medical Virology. 2023. doi:10.1002/jmv.28700
BibTeX
@article{Dia2023,
author = {Dia, Moussa and Bob, Ndeye Sakha and Talla, Cheikh and Dupressoir, Anne and Escadafal, Camille and Thiam, Mareme Seye and Diallo, Amadou and Ndiaye, Oumar and Heraud, Jean Michel and Faye, Oumar and Sall, Amadou Alpha and Faye, Ousmane and Fall, Gamou},
title = {Performance assessment and validation of a plaque reduction neutralization test (PRNT) in support to yellow fever diagnostic and vaccine clinical trials},
journal = {Journal of Medical Virology},
year = {2023},
doi = {10.1002/jmv.28700}
}
EUVIMED